RESUMO
Treatment of patients with metastatic breast cancer is one of the most difficult problems of clinical oncology. Chemotherapy is one of the main methods of treatment of patients with metastatic breast cancer. Long experience of the world's cancer centers, advances in clinical oncology recent decades, the synthesis of anticancer drugs with new mechanisms of action have led to progress in the treatment of disseminated breast cancer. However, as shown by recent studies, the improvement of chemotherapy is not associated with reduced mortality from this disease. This paper presents the effectiveness of anticancer drugs and their combinations in the treatment of patients with metastatic breast cancer. Compliance with which, as it seems to us to produce superior results in treating this disease.
Assuntos
Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama , Terapia Combinada/métodos , Metástase Neoplásica , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/mortalidade , Neoplasias da Mama/patologia , Neoplasias da Mama/terapia , Vias de Administração de Medicamentos , Esquema de Medicação , Feminino , Humanos , Taxa de Sobrevida , Resultado do TratamentoRESUMO
The immunocorrective effect of indomethacin in the course of chemoradiation treatment for inoperable lung cancer was established in a group of 117 patients. It manifested itself in an increase in T-lymphocyte level, normalization of their membrane structure and improvement in immunoregulatory function mainly due to a rise in T-helper/inductor level. Blood plasma-circulating immune complex concentration returned to normal. The concomitant administration of indomethacin during chemoradiation therapy improved subjective status of patients and tumor response but failed to increase survival.
Assuntos
Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/radioterapia , Adjuvantes Imunológicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Pequenas/tratamento farmacológico , Carcinoma de Células Pequenas/radioterapia , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/radioterapia , Indometacina/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/radioterapia , Adenocarcinoma/patologia , Carcinoma de Células Pequenas/imunologia , Carcinoma de Células Pequenas/patologia , Carcinoma de Células Escamosas/imunologia , Carcinoma de Células Escamosas/patologia , Terapia Combinada , Humanos , Neoplasias Pulmonares/imunologia , Neoplasias Pulmonares/patologia , Estadiamento de Neoplasias , Indução de Remissão , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologiaRESUMO
Individual pattern of pharmacokinetics of an antitumor drug platin was investigated in patients with lung cancer. Pharmacokinetic parameters varied considerably with patient, directly influencing the drug efficacy.
